KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Change in Receivables (2016 - 2025)

Biomarin Pharmaceutical (BMRN) has disclosed Change in Receivables for 17 consecutive years, with $120.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Change in Receivables rose 266.34% year-over-year to $120.7 million, compared with a TTM value of $228.1 million through Dec 2025, up 293.81%, and an annual FY2025 reading of $228.1 million, up 293.81% over the prior year.
  • Change in Receivables was $120.7 million for Q4 2025 at Biomarin Pharmaceutical, up from -$48.7 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $138.8 million in Q1 2023 and bottomed at -$72.5 million in Q4 2024.
  • Average Change in Receivables over 5 years is $24.6 million, with a median of $25.6 million recorded in 2021.
  • The sharpest move saw Change in Receivables plummeted 293.25% in 2021, then surged 46462.3% in 2022.
  • Year by year, Change in Receivables stood at -$61000.0 in 2021, then soared by 46462.3% to $28.3 million in 2022, then surged by 106.83% to $58.5 million in 2023, then plummeted by 224.02% to -$72.5 million in 2024, then skyrocketed by 266.34% to $120.7 million in 2025.
  • Business Quant data shows Change in Receivables for BMRN at $120.7 million in Q4 2025, -$48.7 million in Q3 2025, and $98.5 million in Q2 2025.